Publications
326
Citations
8,797
Est. group size
~23
Recurring co-author estimate
Active years
58
Publishing since 1969
Don M. Benson's research centers on multiple myeloma, a cancer of plasma cells, with emphasis on how the immune system—particularly natural killer (NK) cells—can be harnessed or restored to fight this disease. Much of the work involves clinical trials testing new antibody-based and cell-based therapies, including monoclonal antibodies, engineered T cells, and cytokine-based immune therapies, often in patients whose myeloma has relapsed or become resistant to prior treatment.
Publication output grew fairly steadily from 2017 through 2021, spiked sharply in 2023, and has slowed in the most recent years (2024-2026 data likely incomplete).
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Near-Fatal Aspiration of Drug Contraband
Cureus · 2024
- Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma
Blood · 2024
- Supplementary Figure S1-S15 from Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by <i>Ex Vivo</i>–Expanded Autologous NK Cells
2023
- Supplementary Materials and Methods from Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by <i>Ex Vivo</i>–Expanded Autologous NK Cells
2023
- Data from Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by <i>Ex Vivo</i>–Expanded Autologous NK Cells
2023
- Data from Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by <i>Ex Vivo</i>–Expanded Autologous NK Cells
2023
- Supplementary Figure S1-S15 from Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by <i>Ex Vivo</i>–Expanded Autologous NK Cells
2023
- Supplementary Materials and Methods from Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by <i>Ex Vivo</i>–Expanded Autologous NK Cells
2023
- Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood · 2022
- Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission: Results From Cancer and Leukemia Group B 19808
UNC Libraries · 2020
- Storytelling as a means of improving community and decreasing burnout in a large academic cancer center.
Journal of Clinical Oncology · 2020
- Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma
Biology of Blood and Marrow Transplantation · 2020
- Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses
Blood · 2018
- A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
Blood · 2018
- Natural Killer Cell Immunity
Elsevier eBooks · 2017
- Blood×49
- Biology of Blood and Marrow Transplantation×17
- Transplantation and Cellular Therapy×11
- Journal of Clinical Oncology×10
- Leukemia & lymphoma/Leukemia and lymphoma×6
- Don Benson
Medicine · The Ohio State University
- Sherif S. Farag
Medicine · Indiana University
- Yvonne A. Efebera
Medicine · The Ohio State University
- Naresh Bumma
Medicine · The Ohio State University
- Rafat Abonour
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile